Case Report : A Case of Psoriasiform Dermatitis Following Adalimumab Injection for Treatment of Ankylosing Spondylitis
의약학 > 피부과학
( Hyung Jin Hahn ) , ( Jae Wook Jung ) , ( Hyun Jung Park ) , ( Yang Won Lee ) , ( Yong Beom Choe Kyu Joong Ahn )
대한피부과학회지 2013년, 제51권 제9호, 743~745페이지(총3페이지)
27728969.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Adalimumab (HumiraTM) is the first fully humanized monoclonal TNF-αantibody that antagonizes the effects of TNF-α. Its use has been found in the treatment of various rheumatologic disorders, namely rheumatoid arthritis,Crohn``s disease, and ankylosing spondylitis, as well as for various skin conditions such as psoriasis. As the use of this particular biologic agent is becoming more widespread, cutaneous adverse effects of the drug is now being reported at a steady rate. The authors herein report a case of 32 year-old female who presented with multiple psoriasiform eruptions on her trunk, back and lower extremities. She had a four-year history of ankylosing spondylitis,for which she was started on subcutaneous adalimumab injection monthly, three and a half years prior to her initial visit.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.